4th Quarter - Report

PFIZER INC. for PFIZER INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,700,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 20, 2012 $1,700,000 Replaced
4th Quarter - Amendment May 25, 2012 $1,730,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health Care Reform Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives Tax Extenders FDA Funding Antimicrobial Resistance Homeland Security and Agriculture Appropriations Bill on Certified Importer Program Deficit Reduction/Joint Select Committee Issues (Budget Control Act) Vaccines (317 Program appropriations, Immunization Improvements Act) H.R. 965, The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979, FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 H.R. 452, Medicare Decisions Accountability Act S. 1599, FY 2012 Labor HHS Appropriations Bill S. 668, Health Care Bureacrats Elimination Act, 2011

Contacted: Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: S. 1599 (112th), S. 668 (112th), H.R. 979 (112th), H.R. 452 (112th), H.R. 965 (112th)

Consumer Issues/Safety/Products CSP

Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account Supply Chain Issues Counterfeits

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: Food & Drug Administration (FDA); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Patent & Trademark Office (PTO); State, Dept of (DOS); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Trans Pacific Partnership Negotiations

LobbyistCovered position, as disclosed
KEN W COLE —
JOHN PAUL HALLIWELL —
ANGELA WALKER RIEMER —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); Executive Office of the President (EOP); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO)

Copyright/Patent/Trademark CPT

Counterfeit Pharmaceuticals Patent Settlements Stop Online Piracy Act

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
ANGELA WALKER RIEMER —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS)

Medicare/Medicaid MMM

Medicare Rebates/Medicare Part D Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
ANGELA WALKER RIEMER —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Executive Office of the President (EOP)

Taxation/Internal Revenue Code TAX

Repatriation Deferral Tax Extenders Excess Returns/Base Erosion Comprehensive Tax Reform Territorial Systems Patent/Innovation Box H.R. 2735, CFC Look Through Permanency H.R. 1834, Freedom to Invest Act H.R. 2495, Tax Equity and Middle Class Fairness Act (excess returns) S. 1671, The Foreign Earnings Reinvestment Act S. 1346, the Stop Tax Haven Abuse Act

LobbyistCovered position, as disclosed
MARIA CINO —
KEN W COLE —
CAROLINE MOODY SCHELLHAS —

Contacted: State, Dept of (DOS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: S. 1346 (112th), H.R. 1834 (112th), H.R. 2495 (112th), H.R. 2735 (112th), S. 1671 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.